Connect with us

Let's Stop HIV Together: Part 1 - Pharmacology Update: ARVs and Clinical Resources; Part 2: Pharmacology Update: Ceftriaxone and Cabotegravir


Thursday, March 25, 2021 at 8:00pm ET - Wednesday, April 14, 2021 at 9:30pm ET
This event has ended.

Webinar Series



HIV update, including screening, prevention, pharmacology, and more


Diane Bruessow, MPAS, PA-C, DFAAPA; Sam Wijesinghe, DHSc, MS, MPAS, PA-C, AAHIVS; Casey Messer, PA-C; Jonathan Baker, PA-C

Credits Offered

This event offers 2.0 CME credits to attendees.
Accredited by AAPA.

Additional Information

This is a 2-part webinar series cosponsored by the LBGT PA Caucus

Part 1 takes place on March 25, 2021 at 8:00pm EST

Part 2 takes place on April 14, 2021 at 8:30pm EST

Part 1 Description:

For providers not routinely treating HIV, it is important to understand HIV screening, prevention, treatment, ARV pharmacology, and effects of stigma among their patients. While ARVs have evolved significantly over the past 4 decades, over 35,000 HIV infections occur annually in the US many of whom are unaware of their HIV status until late-stage diagnosis. The epidemiology continues to change with infections disproportionately affecting southern states, populations of color, and sexual and gender minorities. Guidelines incorporate screening, prevention and treatment for HIV into routine medical care. utilization of antiretroviral mediated prevention including preexposure prophylaxis and treatment as prevention. While HIV treatment options have significantly improved, long term survivors face new complications including certain cancers and inflammatory mediated disease. HIV is considered a chronic disease, yet the societal stigma surrounding this sexually transmitted disease requires that providers approach HIV with a unique perspective.

Part 2 Description:

While HIV treatment and prevention has evolved significantly over the past 4 decades, over 35,000 HIV infections occur annually in the US. New data, guidelines, and recommendations provide opportunities for progress toward ending the HIV epidemic. Cabotegravir/rilpivirine is the first and only,complete, long-acting injectable treatment for HIV. Cabotegravir is also a candidateĀ  to receive an indication for use asĀ  HIV preexposure prophylaxis (PrEP) following reported data from 2 major clinical trials. STIs can facilitate HIV transmission; therefore, screening for, diagnosis of, and appropriate treatment of bacterial STIs including gonorrhea is essential in the care of people living with and at risk for HIV. Recently, the CDC released new guidelines on the treatment of gonorrhea to recommend an increased, single dose, ceftriaxone-based regimen.